Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vishal Gupta, Ranya Baabbad, Eva Hammerby, Annie Nikolajsen & Asrul Akmal Shafie. (2015) An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. Journal of Medical Economics 18:4, pages 263-272.
Read now
Read now
Anne-Laure Guillermin, Yevgeniy Samyshkin, Donna Wright, Tini Nguyen & Julie Villeneuve. (2011) Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. Journal of Medical Economics 14:2, pages 207-216.
Read now
Read now
Articles from other publishers (12)
Leilani B Mercado-Asis, Mary Jane Tanchee-Ngo, Erick S Mendoza, Ashish Mane, Anand Vasam, Agam Shah & Rishi Jain. (2019) A Prospective, Randomized, Open Label, Single-Centre Study for Assessment of Safety and Effectiveness of Recombinant Human Insulin 30/70 + Insulin Glulisine compared to Recombinant Human Insulin NPH + Regular in the Management of Type 2 Diabetes Mellitus Patients in the Philippines.. Journal of Medicine, University of Santo Tomas 3:1, pages 260-269.
Crossref
Crossref
Katarzyna Nabrdalik, Hanna Kwiendacz, Tomasz Sawczyn, Andrzej Tomasik, Michał Kukla, Małgorzata Masierek & Janusz Gumprecht. (2018) Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study. International Journal of Endocrinology 2018, pages 1-7.
Crossref
Crossref
Kurt Fortwaengler, Christopher G. Parkin, Kurt Neeser, Monika Neumann & Oliver Mast. (2016) Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c). Journal of Diabetes Science and Technology 11:2, pages 315-323.
Crossref
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Amir Farshchi, Rokhsareh Aghili, Maryam Oskuee, Marjan Rashed, Sina Noshad, Abbas Kebriaeezadeh, Maryam Kia & Alireza Esteghamati. (2016) Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Nabil El Naggar & Sanjay Kalra. (2016) Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus. Advances in Therapy 33:12, pages 2091-2109.
Crossref
Crossref
Asrul Akmal Shafie, Vishal Gupta, Ranya Baabbad, Eva Hammerby & Philip Home. (2014) An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Research and Clinical Practice 106:2, pages 319-327.
Crossref
Crossref
Phil McEwan, Volker Foos, James L. Palmer, Mark Lamotte, Adam Lloyd & David Grant. (2014) Validation of the IMS CORE Diabetes Model. Value in Health 17:6, pages 714-724.
Crossref
Crossref
Andreas Liebl, Vinay Prusty, Paul Valensi, Ryuzo Kawamori, Jens Sandahl Christiansen, Andrew J. Palmer, Per Balschmidt, Robert Ligthelm & Viswanathan Mohan. (2012) Ten Years of Experience with Biphasic Insulin Aspart 30. Drugs 72:11, pages 1495-1520.
Crossref
Crossref
Diego Fernández-García & Arantzazu Sebastián-Ochoa. (2012) Insulina aspart en pacientes con diabetes tipo 2. Avances en Diabetología 28, pages 27-31.
Crossref
Crossref
P. Rys, O. Pankiewicz, K. Łach, A. Kwaskowski, I. Skrzekowska-Baran & M.T. Malecki. (2011) Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review. Diabetes & Metabolism 37:3, pages 190-200.
Crossref
Crossref